STOCK TITAN

Director leaves Hologic (HOLX) after $76 cash plus CVR merger payout

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HOLOGIC INC director Charles J. Dockendorff disposed of all his company equity in connection with the company’s merger into Hopper Parent Inc. On the merger’s effective date, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00 in cash when and if payable. All reported non-qualified stock options and common shares, including those held through a revocable trust, were surrendered to the issuer, leaving Dockendorff with no direct or indirect beneficial ownership of Hologic common stock.

Positive

  • None.

Negative

  • None.
Insider Dockendorff Charles J
Role Director
Type Security Shares Price Value
Disposition Non-qualified Stock Option (Right to Buy) 5,396 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 6,523 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 7,322 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 5,055 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 5,293 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 4,210 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 4,536 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 5,535 $0.00 --
Disposition Common Stock 6,626 $0.00 --
Disposition Common Stock 15,370 $0.00 --
Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 0 shares (Direct); Common Stock — 0 shares (Indirect, Revocable Trust)
Footnotes (1)
  1. Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. For Footnote (4), see Remarks below.
Cash consideration per share $76.00 per share Merger consideration for each Hologic common share
Contingent value right potential Up to $3.00 cash Additional CVR amount per Hologic share in merger
Option strike price example $43.24 per share Conversion price on one non-qualified stock option grant
Option strike price example $71.03 per share Conversion price on another non-qualified stock option grant
Common shares disposed (direct) 6,626 shares Common stock directly held and disposed to issuer
Common shares disposed (trust) 15,370 shares Common stock held via revocable trust and disposed to issuer
Derivative transactions reported 8 transactions Non-qualified stock option dispositions on transaction date
Non-derivative transactions reported 2 transactions Common stock dispositions on transaction date
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
contingent value right financial
"one (1) contingent value right, which represents the right to receive up to $3.00 in cash"
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
Non-qualified Stock Option (Right to Buy) financial
"security_title: Non-qualified Stock Option (Right to Buy)"
Merger Consideration financial
"the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration""
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
Revocable Trust financial
"nature_of_ownership: Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dockendorff Charles J

(Last)(First)(Middle)
250 CAMPUS DRIVE

(Street)
MARLBOROUGH MASSACHUSETTS 01752

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/07/2026D6,626D(1)(2)0D
Common Stock04/07/2026D15,370D(1)(3)0IRevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (Right to Buy)$43.2404/07/2026D5,396 (4)05/15/2027Common Stock5,396(4)0D
Non-qualified Stock Option (Right to Buy)$46.8104/07/2026D6,523 (4)03/07/2029Common Stock6,523(4)0D
Non-qualified Stock Option (Right to Buy)$47.3604/07/2026D7,322 (4)03/05/2030Common Stock7,322(4)0D
Non-qualified Stock Option (Right to Buy)$71.0304/07/2026D5,055 (4)03/11/2031Common Stock5,055(4)0D
Non-qualified Stock Option (Right to Buy)$70.2804/07/2026D5,293 (4)03/10/2032Common Stock5,293(4)0D
Non-qualified Stock Option (Right to Buy)$78.4904/07/2026D4,210 (4)03/09/2033Common Stock4,210(4)0D
Non-qualified Stock Option (Right to Buy)$76.3204/07/2026D4,536 (4)03/07/2034Common Stock4,536(4)0D
Non-qualified Stock Option (Right to Buy)$64.3604/07/2026D5,535 (4)02/26/2035Common Stock5,535(4)0D
Explanation of Responses:
1. Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
2. At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
3. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
4. For Footnote (4), see Remarks below.
Remarks:
(4) Pursuant to the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (a "Company Option") with an exercise price per share less than the Cash Consideration was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (A) the number of shares of Company Common Stock subject to such Company Option, multiplied by (B) the excess of the Cash Consideration over the exercise price per share of the Company Option, and (ii) one CVR with respect to each share. Each outstanding Company Option with an exercise price per share equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and $3.00 was cancelled and converted into the right to receive one CVR with respect to each share of Company Common Stock subject to such Company Option, payment in respect of which will be net of the excess of the applicable exercise price per share of the Company Option over $76.00. Each outstanding Company Option with an exercise price per share of Company Common Stock equal to or greater than the sum of the Cash Consideration and $3.00 was cancelled for no consideration.
/s/ Mark W. Irving, attorney-in-fact for Mr. Dockendorff04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Hologic (HOLX) director Charles J. Dockendorff report in this Form 4?

He reported disposing of all his Hologic equity in connection with a completed merger. All listed stock options and common shares, including those in a revocable trust, were surrendered to the issuer, leaving him with no remaining beneficial ownership of Hologic common stock.

How were Hologic (HOLX) common shares treated in the merger?

Each Hologic common share was converted into the right to receive $76.00 in cash plus one contingent value right. The contingent value right provides a potential additional cash payment of up to $3.00 per share if specified conditions are later satisfied.

What happened to Charles J. Dockendorff’s Hologic stock options?

All reported non-qualified stock options were disposed of to the issuer at the merger’s effective time. After these issuer dispositions, the Form 4 shows zero derivative securities remaining, meaning Dockendorff no longer holds Hologic stock options following the transaction.

How were Hologic (HOLX) shares held in a revocable trust affected?

Common shares held indirectly through a revocable trust were also listed as dispositions to the issuer. The filing notes that, as a result of the merger, the reporting person no longer beneficially owns any Hologic common stock, whether held directly or through the revocable trust structure.

What is the contingent value right (CVR) mentioned for Hologic (HOLX)?

The contingent value right is an additional instrument granted per Hologic share in the merger. Each CVR represents the right to receive up to $3.00 in cash in the future, but only if specified conditions outlined in the merger agreement are eventually met.

Does Charles J. Dockendorff still own any Hologic (HOLX) shares after the merger?

According to the Form 4 and its footnotes, he no longer beneficially owns any Hologic common stock. This includes both shares held directly and those previously held indirectly through a revocable trust, reflecting a complete exit from Hologic equity following the merger.